Working… Menu

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03006887
Recruitment Status : Active, not recruiting
First Posted : December 30, 2016
Last Update Posted : April 24, 2019
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Co., Ltd. )

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2020